ID
13423
Beschreibung
Antibiotic-associated diarrhoea (AAD) is a frequent condition in hospitalised patients receiving antibiotic treatment. The same is true for Clostridium difficile-associated diarrhoea (CDAD) with even more grave consequences of increased morbidity and mortality. The development and evaluation of preventive strategies is one key public health challenge. In the absence of clinically evaluated alternatives, probiotics have been suggested to be beneficial for the prevention of AAD and CDAD. However, data have so far been inconclusive and recently published meta-analyses strongly recommended large state-of-the-art clinical trials on probiotic substances for the prevention of AAD and CDAD. Since the efficacy, side-effects and modes of action of different probiotic bacteria and yeast are strain specific, benefits and risks cannot be generalised. The non-pathogenic yeast Saccharomyces cerevisiae var. boulardii (Sac. boulardii) is considered the most promising probiotic substance for the prevention of AAD and CDAD. We carry out a randomised, placebo controlled, double blind multicentre clinical trial to evaluate Sac. boulardii for the indication of prevention of AAD and CDAD in 1520 adult, hospitalised patients.
Stichworte
Versionen (3)
- 04.02.16 04.02.16 -
- 11.02.16 11.02.16 -
- 11.02.16 11.02.16 -
Hochgeladen am
11. Februar 2016
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY-NC 3.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
SacBo TI: Case Report Form Phone Interview Medication Obligatory For Documentation DRKS00000084 NCT01143272
SacBo TI: Case Report Form Phone Interview Medication Obligatory For Documentation NCT01143272
Beschreibung
Treatment with drugs/opiates causing constipation
Beschreibung
line
Datentyp
integer
Beschreibung
medication name
Datentyp
text
Alias
- UMLS CUI [1]
- C2360065
Beschreibung
first dose
Datentyp
date
Alias
- UMLS CUI [1,1]
- C3174092
- UMLS CUI [1,2]
- C0205435
- UMLS CUI [1,3]
- C0011008
Beschreibung
Date of first dose unknown
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C3174092
- UMLS CUI [1,2]
- C0205435
- UMLS CUI [1,3]
- C0439673
- UMLS CUI [1,4]
- C0011008
Beschreibung
Date of last dose
Datentyp
date
Alias
- UMLS CUI [1]
- C1762893
Beschreibung
Date of last dose unknown
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C1762893
- UMLS CUI [1,2]
- C0439673
Beschreibung
Treatment with systemic antifungal agents; note that the use of systemic antifungal agents makes the patient retrospectively ineligible for this study as of exclusion criterion 06; please record early study termination if this is the case
Beschreibung
Line
Datentyp
integer
Beschreibung
medication name
Datentyp
text
Alias
- UMLS CUI [1]
- C2360065
Beschreibung
first dose
Datentyp
date
Alias
- UMLS CUI [1,1]
- C3174092
- UMLS CUI [1,2]
- C0205435
- UMLS CUI [1,3]
- C0011008
Beschreibung
Date of first dose unknown
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C3174092
- UMLS CUI [1,2]
- C0205435
- UMLS CUI [1,3]
- C0439673
- UMLS CUI [1,4]
- C0011008
Beschreibung
Date of last dose
Datentyp
date
Alias
- UMLS CUI [1]
- C1762893
Beschreibung
Date of last dose unknown
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C1762893
- UMLS CUI [1,2]
- C0439673
Ähnliche Modelle
SacBo TI: Case Report Form Phone Interview Medication Obligatory For Documentation NCT01143272
C1515021 (UMLS CUI [1,2])
C0205435 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
C0003232 (UMLS CUI [1,2])
C0205435 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
C0205435 (UMLS CUI [1,2])
C0439673 (UMLS CUI [1,3])
C0011008 (UMLS CUI [1,4])
C0439673 (UMLS CUI [1,2])
C0205435 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
C0205435 (UMLS CUI [1,2])
C0439673 (UMLS CUI [1,3])
C0011008 (UMLS CUI [1,4])
C0439673 (UMLS CUI [1,2])
Keine Kommentare